2022
Benefit of Extended Surveillance of Low-Risk Pancreatic Cysts After 5-Year Stability: A Systematic Review and Meta-Analysis
Chhoda A, Singh S, Sheth AH, Grimshaw AA, Gunderson C, Sharma P, Kunstman JW, Sharma A, Ahuja N, Gonda TA, Farrell JJ. Benefit of Extended Surveillance of Low-Risk Pancreatic Cysts After 5-Year Stability: A Systematic Review and Meta-Analysis. Clinical Gastroenterology And Hepatology 2022, 21: 1430-1446. PMID: 35568304, DOI: 10.1016/j.cgh.2022.04.025.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Pancreatic DuctalHumansPancreatic CystPancreatic DuctsPancreatic Intraductal NeoplasmsPancreatic NeoplasmsRetrospective StudiesConceptsDisease-specific mortalityAdvanced neoplasiaBD-IPMNsExtended surveillancePooled incidenceWorrisome featuresSystematic reviewIntraductal papillary mucinous neoplasmHigh-grade dysplasiaPapillary mucinous neoplasmHigh-quality studiesRandom-effects modelWarrants further investigationWeb of ScienceNeoplasia incidenceWarrants further explorationSurvival benefitCochrane LibraryMucinous neoplasmsPancreatic cancerPancreatic cystsSurveillance periodEligible studiesOvid MEDLINELower incidenceClinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review
Grant SJ, Grimshaw AA, Silberstein J, Murdaugh D, Wildes TM, Rosko AE, Giri S. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review. Transplantation And Cellular Therapy 2022, 28: 294-302. PMID: 35288347, PMCID: PMC9197870, DOI: 10.1016/j.jtct.2022.03.006.Peer-Reviewed Original ResearchConceptsImmune effector cell-associated neurotoxicity syndromeCAR T-cell therapyT-cell therapyLong-term outcomesHematologic malignanciesCell therapyClinical presentationLymphocytic leukemiaCAR-T cell therapy recipientsChimeric antigen receptor T-cell therapyJoanna Briggs Institute critical appraisal toolsDiffuse large B-cell lymphomaCAR T-cell productsLarge B-cell lymphomaCytokine release syndromeRefractory hematologic malignanciesLong-term sequelaeSubset of patientsC-reactive proteinCommon hematologic malignancyLife-threatening conditionNon-Hodgkin lymphomaCross-trial comparisonsAcute lymphocytic leukemiaChronic lymphocytic leukemia
2021
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis
Bewersdorf JP, Sheth AH, Vetsa S, Grimshaw A, Giri S, Podoltsev NA, Gowda L, Tamari R, Tallman MS, Rampal RK, Zeidan AM, Stahl M. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis. Transplantation And Cellular Therapy 2021, 27: 873.e1-873.e13. PMID: 34052505, PMCID: PMC8478722, DOI: 10.1016/j.jtct.2021.05.016.Peer-Reviewed Original ResearchMeSH KeywordsGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansPrimary MyelofibrosisRetrospective StudiesTransplantation ConditioningConceptsConditioning regimen intensityAllo-HCTRegimen intensityChronic graftTransplant characteristicsGraft failureOverall survivalPatient ageSubgroup analysisDynamic International Prognostic Scoring System scoresSystematic reviewAllogeneic hematopoietic cell transplantationInternational Prognostic Scoring System scoreCurative therapeutic modalityNon-relapse mortalityTransplant-related mortalityMedian patient ageOutcomes of patientsSecondary graft failureCo-primary outcomesHematopoietic cell transplantHematopoietic cell transplantationRandomized clinical trialsHeterogeneity of patientsRandom-effects model